​We hypothesize that some chemotherapeutics can cause DNA mutations that are translated into proteins and peptides that make their way into the MHC class I peptide presentation pathway. If these neoantigens are seen by CD8+ T cells as foreign, T cells will attack these tumor cells. This could provide one mechanism of action for an increase in therapeutic efficacy in tumors treated with combinations of chemotherapeutics and checkpoint inhibitors. We tested the ability of two drugs, SN-38 (an active metabolite of irinotecan) and oxaliplatin, to induce neoantigens by sequencing peptides from class I molecules in a colon cancer cell line.

Do you have a question or comment for the presenter? Let us know.

To cite this poster: Rumble, J., Mobley, J., Jones, R., et al. Chemotherapeutic drug-induced tumor neoantigen discovery. Poster presented at: 2019 American Association for Cancer Research (AACR) Annual Meeting; March 29-April 3, 2019; Atlanta, GA.